13 independently checked trend briefs about this subject, newest first.
headlinez.news detected 13 source-qualified news clusters connected to Eli Lilly between June 23, 2026 and July 24, 2026. They span 2 newsroom categories and average 7.5 independent sources per brief.
This hub includes only briefs supported by at least four sources and passed by the site's verification gate. Raw or weak detections may exist but are excluded here. Topic matching is based on the entities and themes recorded with each brief; open a card to inspect its source links, publication time, verification label and velocity history. Read the methodology and editorial policy for the full rules.
Eli Lilly shares rise as new trial data shows the weight-loss drug retatrutide led to an average weight loss of 56 pounds.
Eli Lilly's $3.8 billion acquisition of a psychedelic company draws industry attention to the firm’s renewed focus on neuropsychiatry and Alzheimer's prevention.
Eli Lilly plans regulatory filings for its weight-loss drug retatrutide following successful Phase 3 trial results.
Novo Nordisk has launched a lawsuit against Eli Lilly, challenging the advertising claims made by the competitor regarding their weight-loss medications.
Novo Nordisk has launched legal action against Eli Lilly, alleging that its rival engaged in deceptive marketing practices regarding weight-loss medications.
Biotech IPO test: Scribe Therapeutics targets $75M valuation amid early-stage investor scrutiny
The FDA has launched its PreCheck pilot program, selecting seven participants to accelerate domestic drug manufacturing capabilities.
Eli Lilly stock surges to record highs amid EU approvals and market rotation
The FDA has selected Eli Lilly and Regeneron for a pilot program designed to accelerate the review process for new pharmaceutical manufacturing facilities.
Eli Lilly’s stock surges as EU panel fast-tracks approvals for two blockbuster drugs, reshaping investor and patient expectations
New oral GLP-1 medications are moving into focus as Eli Lilly and Company evaluates their broader impact on public health.
Public scrutiny intensifies over the identity of an anonymous 79-year-old patient granted compassionate access to Eli Lilly’s experimental obesity drug, retatrutide.
Gene therapy pioneer Sangamo Therapeutics files for bankruptcy, with Lilly and Astellas racing to acquire its assets